AdultPediatricGeriatricDosage Forms Strengths tablets (Zoloft, generic) 25mg 50mg 100mg capsules (generic) 150mg 200mg oral solution (Zoloft, generic) 20mg/mL Major depressive disorder Indicated for major depressive disorder (MDD) Tablets Initial dose: 50 mg PO qDay May increase by 25 mg at weekly intervals; not to exceed 200 mg qDay Capsules Do not use to initiate treatment; only available as 150-mg or 200-mg doses Use another sertraline HCl product for initial dosage, titration, and dosages below 150 mg qDay Refer to prescribing information of other sertraline HCl products for the recommended dosage for those products May initiate capsules in patients receiving 100 mg or 125 mg of another sertraline HCl product for at least 1 week Recommended dosage: 150 mg or 200 mg PO qDay; not to exceed 200 mg qDay Obsessive-Compulsive Disorder Indicated for obsessive-compulsive disorder (OCD) Tablets Initial dose: 50 mg PO qDay May increase by 25 mg at weekly intervals; not to exceed 200 mg qDay Capsules Do not use to initiate treatment; only available as 150-mg or 200-mg doses Use another sertraline HCl product for initial dosage, titration, and dosages below 150 mg qDay Refer to prescribing information of other sertraline HCl products for the recommended dosage for those products May initiate capsules in patients receiving 100 mg or 125 mg of another sertraline HCl product for at least 1 week Recommended dosage: 150 mg or 200 mg PO qDay; not to exceed 200 mg qDay Panic Disorder Tablets only Indicated for panic disorder (PD) Initial: 25 mg PO qDay May increase by 25 mg at weekly intervals; not to exceed 200 mg qDay Posttraumatic Stress Disorder Tablets only Indicated posttraumatic stress disorder (PTSD) Initial: 25 mg PO qDay May increase by 25 mg at weekly intervals; not to exceed 200 mg qDay Social Anxiety Disorder Tablets only Indicated for social anxiety disorder (SAD) Initial: 25 mg PO qDay May increase by 25 mg at weekly intervals; not to exceed 200 mg qDay Premenstrual Dysphoric Disorder Tablets only Indicated for premenstrual dysphoric disorder (PMDD) Continuous dosing Initial: 50 mg per day continuously (every day throughout the menstrual cycle) May increase by 50 mg per menstrual cycle to up to 150 mg per day if necessary Intermittent dosing Initial: 50 mg per day intermittently (only during the luteal phase of the menstrual cycle, ie, starting daily dosage 14 days before the anticipated onset of menstruation and continuing through the onset of menses) Repeat intermittent dosing with each new cycle May increase to a maximum 100 mg per day during the next menstrual cycle Subsequent cycles: 50 mg/day during the first 3 days of dosing followed by 100 mg/day during the remaining days in the dosing cycle Dosage Modifications Renal impairment All severities (eGFR 15-89 mL/min/1.73 m2): No dosage adjustment necessary Sertraline exposure does not appear to be affected by renal impairment Hepatic impairment Capsules: Dosage adjustments are not possible with available dosage strengths Tablets Mild (Child Pugh scores 5 or 6): Reduce starting and therapeutic range by half the recommended daily dosage; dosage adjustments are not possible with capsules Moderate-to-severe (Child Pugh scores 7-15): Not recommended Dosing Considerations Before initiating treatment Before initiating treatment, screen for personal or family history of bipolar disorder, mania, or hypomania Switching to or from a monoamine oxidase inhibitor (MAOI) When switching to or from a MAOI antidepressant, at least 14 days must elapse between discontinuing MAOI antidepressant and initiating sertraline Additionally, at least 14 days must elapse after stopping sertraline capsules before starting an MAOI antidepressant Discontinuation of sertraline HCl capsules Abrupt discontinuation may result in adverse effects including nausea, sweating, dysphoric mood, irritability, agitation, dizziness, sensory disturbances (eg, paresthesia, tremor, anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures Gradually taper dose over at least several weeks to limit possibilities of withdrawal symptoms and detection of re-emerging symptoms Consider the half-life of antidepressant when tapering; those with a shorter half-life may require longer and more conservative dose reductions Capsules only Given that dosage strengths lower than 150 mg are not available, gradual dosage reduction will require the use of another sertraline HCl product Dosage Forms & Strengths tablets (Zoloft, generic) 25mg 50 mg 100mg capsules (generic) 150mg 200mg oral solution (Zoloft, generic) 20mg/mL Obsessive-Compulsive Disorder Indicated for obsessive-compulsive disorder (OCD) in adults and children aged ≥6 years <6 years: Safety and efficacy not established Tablets 6-12 years: 25 mg PO qDay initially 12-17 years: 50 mg PO qDay initially May increase by 50 mg qDay at weekly intervals, not to exceed 200 mg qDay; give qHS if somnolence experienced Capsules Do not use to initiate treatment; only available as 150-mg or 200-mg doses Use another sertraline HCl product for initial dosage, titration, and dosages below 150 mg qDay Refer to prescribing information of other sertraline HCl products for the recommended dosage for those products May initiate capsules in patients receiving 100 mg or 125 mg of another sertraline HCl product for at least 1 week Recommended dosage: 150 mg or 200 mg PO qDay; not to exceed 200 mg qDay Dosage Modifications Renal impairment All severities (eGFR 15-89 mL/min/1.73 m2): No dosage adjustment necessary Sertraline exposure does not appear to be affected by renal impairment Hepatic impairment Capsules: Dosage adjustments are not possible with available dosage strengths Tablets Mild (Child Pugh scores 5 or 6): Reduce starting and therapeutic range by half the recommended daily dosage; dosage adjustments are not possible with capsules Moderate-to-severe (Child Pugh scores 7-15): Not recommended Dosing Considerations Before initiating treatment Before initiating treatment, screen for personal or family history of bipolar disorder, mania, or hypomania Switching to or from a monoamine oxidase inhibitor (MAOI) When switching to or from a MAOI antidepressant, at least 14 days must elapse between discontinuing MAOI antidepressant and initiating sertraline Additionally, at least 14 days must elapse after stopping sertraline capsules before starting an MAOI antidepressant Discontinuation of sertraline HCl capsules Abrupt discontinuation may result in adverse effects including nausea, sweating, dysphoric mood, irritability, agitation, dizziness, sensory disturbances (eg, paresthesia, tremor, anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures Gradually taper dose over at least several weeks to limit possibilities of withdrawal symptoms and detection of re-emerging symptoms Consider the half-life of antidepressant when tapering; those with a shorter half-life may require longer and more conservative dose reductions Capsules only Given that dosage strengths lower than 150 mg are not available, gradual dosage reduction will require the use of another sertraline HCl product The elderly are prone to SSRI/SNRI-induced hyponatremia; monitor closely Major Depressive Disorder 25 mg PO qDay initially; may increase by 25 mg every 2-3 days; not to exceed 200 mg qDay Alzheimer dementia related depression: Start at 12.5 mg/day and titrate every 1-2 weeks to response; not to exceed 150-200 mg Dosage Modifications Renal impairment: Dose adjustment not necessary Mild hepatic impairment (Child-Pugh 5-6): Decrease recommended starting dose and therapeutic dose by 50% Moderate-to-severe hepatic impairment (Child-Pugh 7-15): Not recommended; sertraline is extensively metabolized, and the effects in patients with moderate and severe hepatic impairment have not been studiedInteraction CheckerEnter a drug name and sertralineNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (14)dronedaronesertraline and dronedarone both increase QTc interval. Contraindicated.eliglustatsertraline increases levels of eliglustat by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. If coadministered with strong or moderate CYP2D6 inhibitors, reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive and intermediate metabolizers; eliglustat is contraindiated if strong or moderate CYP2D6 inhibitors are given concomitantly with strong or moderate CYP3A inhibitors.fezolinetantsertraline will increase the level or effect of fezolinetant by affecting hepatic enzyme CYP1A2 metabolism. Contraindicated. Fezolinetant AUC and peak plasma concentration are increased if coadministered with drugs that are weak, moderate, or strong CYP1A2 inhibitorsflibanserinsertraline will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration of flibanserin with moderate or strong CYP3A4 inhibitors is contraindicated. Severe hypotension or syncope can occur.isocarboxazidisocarboxazid and sertraline both increase serotonin levels. Contraindicated.lomitapidesertraline increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Increases lomitapide levels several folds.lonafarnibsertraline will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is a sensitive CYP3A4 substrate. Coadministration with strong or moderate CYP3A4 inhibitors is contraindicated. mavacamtensertraline will increase the level or effect of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. phenelzinephenelzine and sertraline both increase serotonin levels. Contraindicated.pimozidesertraline increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of prolonged QTc interval.procarbazineprocarbazine and sertraline both increase serotonin levels. Contraindicated. Combination is contraindicated within 2 weeks of MAOI use.selegilineselegiline and sertraline both increase serotonin levels. Contraindicated. At least 14 days should elapse between discontinuation of selegiline and initiation of treatment with a serotonergic drug.thioridazinesertraline increases levels of thioridazine by decreasing metabolism. Contraindicated. Risk of long QT syndrome.sertraline and thioridazine both increase QTc interval. Contraindicated.tranylcyprominetranylcypromine and sertraline both increase serotonin levels. Contraindicated.Serious - Use Alternative (157)adagrasibadagrasib, sertraline. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients.alfentanilalfentanil, sertraline. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.amiodaronesertraline and amiodarone both increase QTc interval. Avoid or Use Alternate Drug.amisulprideamisulpride and sertraline both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.amitriptylinesertraline and amitriptyline both increase serotonin levels. Avoid or Use Alternate Drug.amoxapinesertraline and amoxapine both increase serotonin levels. Avoid or Use Alternate Drug.anagrelidesertraline and anagrelide both increase QTc interval. Avoid or Use Alternate Drug.apalutamideapalutamide will decrease the level or effect of sertraline by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP2C19 inducer, with drugs that are CYP2C19 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered.arsenic trioxidesertraline and arsenic trioxide both increase QTc interval. Avoid or Use Alternate Drug.artemetherartemether and sertraline both increase QTc interval. Avoid or Use Alternate Drug.artemether/lumefantrinesertraline and artemether/lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.asenapinesertraline and asenapine both increase QTc interval. Avoid or Use Alternate Drug.asenapine transdermalasenapine transdermal and sertraline both increase QTc interval. Avoid or Use Alternate Drug.avapritinibsertraline will increase the level or effect of avapritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of avapritinib with moderate CYP3A4 inhibitors. If unable to avoid, reduce avapritinib starting dose. See drug monograph Dosage Modifications.axitinibsertraline increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid coadministration with moderate CYP3A4 inhibitors, monitor closely and reduce dose if necessary .bosutinibsertraline increases levels of bosutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.buprenorphinesertraline and buprenorphine both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine buccalbuprenorphine buccal and sertraline both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine subdermal implantbuprenorphine subdermal implant and sertraline both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine transdermalbuprenorphine transdermal and sertraline both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine, long-acting injectionbuprenorphine, long-acting injection and sertraline both increase QTc interval. Avoid or Use Alternate Drug.buspironesertraline and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.ceritinibceritinib and sertraline both increase QTc interval. Avoid or Use Alternate Drug.chlorpromazinesertraline and chlorpromazine both increase QTc interval. Avoid or Use Alternate Drug.citalopramcitalopram and sertraline both increase serotonin levels. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.citalopram and sertraline both increase QTc interval. Avoid or Use Alternate Drug.clarithromycinclarithromycin and sertraline both increase QTc interval. Avoid or Use Alternate Drug.clomipraminesertraline and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug.sertraline and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.cobimetinibsertraline will increase the level or effect of cobimetinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If concurrent short term (14 days or less) use of moderate CYP3A inhibitors is unavoidable for patients who are taking cobimetinib 60 mg, reduce the